Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 5/20 | 0.71 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.71 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.71 |
| ▸ | DRD2 | P14416 | 2/20 | 0.59 |
| ▸ | DRD4 | P21917 | 2/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.59 |
| ▸ | BCHE | P06276 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | ALPL | P05186 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10349438 | 0.89 | DRD2 (0.62) | ADRB2TBXA2RADRB1DRD2DRD4 | |
| SCHEMBL10802171 | 0.86 | DRD2 (0.63) | ADRB2TBXA2RADRB1DRD2DRD4 | |
| SCHEMBL10349433 | 0.84 | ADRB2 (0.72) | ADRB2DRD2DRD4KDM1ABCHE | |
| SCHEMBL10348905 | 0.84 | DRD2 (0.60) | ADRB2TBXA2RDRD2DRD4KDM1A | |
| SCHEMBL5899131 | 0.83 | ADRB2 (1.00) | ADRB2TBXA2RADRB1DRD2DRD4 | |
| SCHEMBL5919602 | 0.82 | ADRB2 (0.74) | ADRB2TBXA2RADRB1DRD2DRD4 | |
| SCHEMBL10348610 | 0.82 | DRD2 (0.78) | ADRB2TBXA2RDRD2DRD4KDM1A | |
| SCHEMBL10348861 | 0.82 | BCHE (0.61) | ADRB2TBXA2RADRB1DRD2DRD4 | |
| SCHEMBL10349436 | 0.81 | TBXA2R (0.74) | ADRB2TBXA2RADRB1BCHEKDM4E | |
| SCHEMBL10348897 | 0.78 | BCHE (0.74) | ADRB2TBXA2RADRB1DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007036543-A1 | BETA-3-AGONIST USE FOR TREATING KIDNEY AND BLADDER TROUBLES OF A PATIENT WITH SPINAL CORD DAMAGES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-04-05 | — | — | WO | disclosed |
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | MICHEL MARTIN C | 2007-04-05 | — | — | US | disclosed |
| EP-1769792-A1 | Use of a beta-3 adrenoceptor agonist for the treatment of renal and bladder problems | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2007-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078181-A1 | Use of a beta-3-agonist for the treatment of patients with spinal cord injury and suffering from renal and bladder complaints | ADRB3, ADRB2, ADRB1 | ADRB2 2/4885TBXA2R 157/4885ADRB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.